Cancer Aware · Patient & Family Guide

FIGO Staging Explained

Stage describes the extent of cancer. This guide uses the FIGO 2018 framework with corrected boundaries reproduced in the FIGO Cancer Report 2025; older reports and trials may use FIGO 2009 or 2014.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 10 of 25

FIGO staging: regions involvedConceptual region map: stage I is confined to the cervix; stage II may involve upper vagina or parametrium; stage III includes lower vagina, pelvic wall, tumour-related kidney obstruction or regional lymph nodes; stage IV includes adjacent organ mucosa or distant spread. Regions are schematic and not to anatomical scale.I: CervixII: Nearby extensionIII: Lower vagina / pelvic wallor regional nodes / kidney obstructionIV: Organ mucosa or distant spread
Conceptual extent map, not an anatomical measurement tool. Nodes can determine stage IIIC regardless of primary tumour size. See the table for exact substages and qualifications.
At a glance: FIGO Staging Explained
  1. I: within cervix
  2. II: beyond uterus, not lower vagina or pelvic wall
  3. III: lower vagina, pelvic wall, kidneys or regional nodes
  4. IV: adjacent organ mucosa or distant disease

What you will learn

Understand stages and substages; interpret lymph-node suffixes; recognize why different staging editions cannot be exchanged casually.

Stage-by-stage reference

StagePatient-friendly definition
IConfined to the cervix; extension to the uterine body is disregarded for this classification
IAInvasion detectable only microscopically, no more than 5 mm deep
IA1Invasion no more than 3 mm deep
IA2Invasion more than 3 mm and no more than 5 mm deep
IBInvasion deeper than 5 mm, still confined to the cervix
IB1Tumour no more than 2 cm in greatest dimension
IB2More than 2 cm and no more than 4 cm
IB3More than 4 cm
IIBeyond the uterus, but not the lower third of vagina or pelvic wall
IIA1 / IIA2Upper two-thirds vaginal involvement without parametrial invasion; no more than 4 cm / more than 4 cm
IIBParametrial involvement without reaching the pelvic wall
IIIALower-third vaginal involvement without pelvic-wall extension
IIIBPelvic-wall extension and/or tumour-related hydronephrosis or a nonfunctioning kidney
IIIC1Pelvic lymph-node metastasis
IIIC2Para-aortic lymph-node metastasis
IVASpread to adjacent pelvic organs, including confirmed bladder or rectal mucosal involvement
IVBDistant spread, such as distant organs or nonregional nodes

How stage is established

Examination, imaging and pathology may all contribute. Pathological findings take precedence when available. For IIIC, “r” indicates imaging-based nodal staging and “p” indicates pathological confirmation. Micrometastases count as nodal disease; isolated tumour cells alone do not change the stage. A clinician must interpret the full report, including deposit size and location.

Lymphovascular space invasion means cancer cells are seen in small vessels. It can affect treatment choices but does not by itself change the FIGO stage. Likewise, grade and tumour biomarkers are different from stage. Tumour-related kidney obstruction has a staging role; obstruction from an unrelated cause should not be automatically attributed to the cancer.

Important boundaries and limitations

A microscopic depth of exactly 3 mm lies in IA1 in the corrected framework, and exactly 5 mm in IA2. For stage IB size divisions, exactly 2 cm lies in IB1 and exactly 4 cm in IB2. These measurements require appropriate pathological or clinical assessment; they are not measurements a patient should infer from symptoms or a photograph.

Swelling of the bladder lining alone does not establish IVA. The team may need direct examination and biopsy when mucosal invasion is suspected. Regional nodes do not automatically mean IVB. Two people labelled IIIC can have quite different primary tumours and outlooks, so stage must be interpreted with the complete disease pattern.

Stage and treatment are related, not identical

Very early disease may be treated surgically, sometimes preserving fertility. Larger or locally advanced disease commonly needs chemoradiation and brachytherapy. Selected high-risk patients may also receive immunotherapy under the relevant regional indication. IVB usually requires systemic treatment and symptom-directed care, with local approaches considered selectively. Stage alone cannot select the exact regimen.

Misconception and common question

“Stage III always means distant metastases” is false. Why does an immunotherapy label mention FIGO 2014? It reflects the trial and approval framework; clinicians must map the actual disease extent, not simply substitute a FIGO 2018 number.

Take-home messages

Ask for stage, edition and supporting findings. Use the stage explorer to learn definitions, not to stage yourself. Request an explanation of both local tumour extent and nodal status.

References and review status

Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy